ArticlePloS one2010
The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Matcha Green Tea Powder does not Prevent Diet-Induced Arteriosclerosis in New Zealand White Rabbits Due to Impaired Reverse Cholesterol Transport.Molecular nutrition & food research · 2021Article
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.Thyroid : official journal of the American Thyroid Association · 2019Review
- Direct effects of thyroid hormones on hepatic lipid metabolism.Nature reviews. Endocrinology · 2018Review
- Chronic vitamin A-enriched diet feeding regulates hypercholesterolaemia through transcriptional regulation of reverse cholesterol transport pathway genes in obese rat model of WNIN/GR-Ob strain.The Indian journal of medical research · 2016Article
- Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.Current atherosclerosis reports · 2016Review
- 3,5,3'-Triiodo-L-Thyronine- and 3,5-Diiodo-L-Thyronine- Affected Metabolic Pathways in Liver of LDL Receptor Deficient Mice.Frontiers in physiology · 2016Article
- The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism.Cell metabolism · 2014Article
- Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT.Journal of lipid research · 2014Article
- Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.EMBO molecular medicine · 2014Article
- Hepatic nuclear corepressor 1 regulates cholesterol absorption through a TRβ1-governed pathway.The Journal of clinical investigation · 2014Article
- Thyroid hormone analogues and derivatives: Actions in fatty liver.World journal of hepatology · 2014Review
- New avenues for regulation of lipid metabolism by thyroid hormones and analogs.Frontiers in physiology · 2014Review
- Nuclear receptors and their selective pharmacologic modulators.Pharmacological reviews · 2013Review
- Is the future of statins aligned with new novel lipid modulation therapies?Current atherosclerosis reports · 2013Review
- Article
- Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor.Endocrinology · 2012Article
- Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.Endocrinology · 2012Article
- Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Nutrition & metabolism · 2012Article
- Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the ABCA1 transporter.Atherosclerosis · 2011Article
- Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport.World journal of gastroenterology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundLiver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the scavenger receptor class B type I (SR-BI). Here, we investigated the effect of the thyromimetic T-0681 on reverse cholesterol transport (RCT) and atherosclerosis, and studied the underlying mechanisms using different mouse models, including mice lacking LDLr, SR-BI, and apoE, as well as CETP transgenic mice. METHODOLOGY/PRINCIPAL
findingsT-0681 treatment promoted bile acid production and biliary sterol secretion consistently in the majority of the studied mouse models, which was associated with a marked reduction of plasma cholesterol. Using an assay of macrophage RCT in mice, we found T-0681 to significantly increase fecal excretion of macrophage-derived neutral and acidic sterols. No positive effect on RCT was found in CETP transgenic mice, most likely due to the observed decrease in plasma CETP mass. Studies in SR-BI KO and LDLr KO mice suggested hepatic LDLr to be necessary for the action of T-0681 on lipid metabolism, as the compound did not have any influence on plasma cholesterol levels in mice lacking this receptor. Finally, prolonged treatment with T-0681 reduced the development of atherosclerosis by 60% in apoE KOs on Western type diet. In contrast, at an earlier time-point T-0681 slightly increased small fatty streak lesions, in part due to an impaired macrophage cholesterol efflux capacity, when compared to controls. CONCLUSIONS/SIGNIFICANCE: The present results show that liver-selective thyromimetics can promote RCT and that such compounds may protect from atherosclerosis partly through induction of bile acid metabolism and biliary sterol secretion. On-going clinical trials will show whether selective thyromimetics do prevent atherosclerosis also in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.